Product Reviews
Categories
- Alternative Medicine
- Cancer
- Acute Promyelocytic Leukemia
- Anal Cancer
- Bladder Cancer
- Breast cancer
- Colorectal cancer
- Endometrial Cancer
- Esophageal Cancer
- Gallbladder cancer
- Gastric Cancer
- Glioblastma
- Head and Neck Cancer
- Liver Cancer
- Lung Cancer
- Lymphoma
- Melanoma
- Nasopharyngeal Cancer
- Non-Hodgkin's Disease
- Ovarian Cancer
- Pancreatic Cancer
- Prostate cancer
- Renal Cancer
- Thyroid Cancer
- Cardiovascular disease
- Central Nervous System
- Constipation
- Diabetes
- Fatty Liver
- Irritable Bowel Syndrome
- Longevity
- Motherhood
- Obesity
- Others
- Psoriasis
- Respiratory Disease
- Rheumatoid Arthritis
Archives
Tag Archives: sipuleucel-T
New Prostate Cancer Agent Improves Survival by Nearly 5 Months!
Excellent news for prostate cancer patients whose cancer has progressed after hormonal treatment and chemotherapy! An experimental oral agent, MDV3100 (Medivation) was found to improve survival in metastatic castration-resistant prostate cancer by 4.8 months The new agent, called MDV3100, is … Continue reading →
Posted in Cancer, Prostate cancer
|
Tagged abiraterone, AFFIRM, bicalutamide, cabazitaxel, Casodex, docetaxel, Drogenil, flutamide, Jevtana, MDV3100, Medivation, metastatic castration-resistant prostate, Prostate cancer, Provenge, sipuleucel-T, Survival, Taxotere, Zytiga
|
Comments Off on New Prostate Cancer Agent Improves Survival by Nearly 5 Months!
A New Agent That Might Change the Lives of Many Cancer Patients
This is not only good news for all prostate cancer patients, but is also good news for all cancer patients. The investigational radiopharmaceutical radium-223 chloride (Alpharadin) has recently been shown to improve survival in patients with advanced prostate cancer and … Continue reading →
Posted in Anal Cancer, Bladder Cancer, Breast cancer, Cancer, Colorectal cancer, Endometrial Cancer, Esophageal Cancer, Gallbladder cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma, Nasopharyngeal Cancer, Non Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate cancer, Renal Cancer, Small Cell Lung Cancer, Thyroid Cancer
|
Tagged abiraterone, advanced prostate cancer, Alpharadin, ALSYMPCA, bone metastases, Cancer, carbitaxel, docetaxel, immunotherapy, Jevtana, Prostate cancer, Provenge, radium-223 chloride, sipuleucel-T, Stage IV cancers, Survival, Taxotere, Zytiga
|
Comments Off on A New Agent That Might Change the Lives of Many Cancer Patients
New Prostate Cancer Drug Approved by FDA
Good news for patients with metastatic prostate cancer. The FDA (US Food and Drug Administration) has approved Johnson & Johnson’s Zytiga (abiraterone) in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy. Abiraterone … Continue reading →
Posted in Cancer, Prostate cancer
|
Tagged abiraterone, cabazitaxel, FDA, Jevtana, Johnson & Johnson, metastatic, Prostate cancer, Provenge, sipuleucel-T, Zytiga
|
1 Comment
FDA Approves the First Immunotherapy, Provenge, for Metastatic Prostate Cancer
For men with advanced metastatic prostate cancer that did not respond to hormone therapy, there is a new hope for improved survival. FDA has approved an immunotherapy sipuleucel-T (Provenge, Dendreon), for the treatment of asymptomatic or minimally symptomatic metastatic, castration-resistant … Continue reading →
Posted in Cancer, Prostate cancer
|
Tagged Dendreon, immunotherapy, metastatic prostate cancer, Provenge, sipuleucel-T, Survival
|
Comments Off on FDA Approves the First Immunotherapy, Provenge, for Metastatic Prostate Cancer
